311 related articles for article (PubMed ID: 22048000)
1. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O; Michels RM; Massard C; de Bono JS
Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
[TBL] [Abstract][Full Text] [Related]
2. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Bahl A
Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
[TBL] [Abstract][Full Text] [Related]
3. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
4. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
5. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
9. Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC; Smaletz O; Herchenhorn D
Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
[TBL] [Abstract][Full Text] [Related]
10. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
[TBL] [Abstract][Full Text] [Related]
11. [Second line therapy for castration-resistant prostate cancer (CRPC)].
Molitor B; Börgermann C
Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
[TBL] [Abstract][Full Text] [Related]
12. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Sartor AO
J Hematol Oncol; 2011 Apr; 4():18. PubMed ID: 21513551
[TBL] [Abstract][Full Text] [Related]
13. New agents for the management of castration-resistant prostate cancer.
Cersosimo RJ
Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
[TBL] [Abstract][Full Text] [Related]
14. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
Gravanis I; Lopez AS; Hemmings RJ; Jiménez JC; Garcia-Carbonero R; Gallego IG; Giménez EV; O'Connor D; Giuliani R; Salmonson T; Pignatti F
Oncologist; 2013; 18(9):1032-42. PubMed ID: 23966222
[TBL] [Abstract][Full Text] [Related]
15. New treatment options for patients with metastatic castration-resistant prostate cancer.
Higano CS
Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone and its place in the treatment of metastatic CRPC.
Sartor O; Pal SK
Nat Rev Clin Oncol; 2013 Jan; 10(1):6-8. PubMed ID: 23149889
[TBL] [Abstract][Full Text] [Related]
17. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
18. Current clinical trials in castrate-resistant prostate cancer.
Petrylak DP
Curr Urol Rep; 2011 Jun; 12(3):173-9. PubMed ID: 21533748
[TBL] [Abstract][Full Text] [Related]
19. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
20. [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Heck MM; Höppner M; Horn T; Thalgott M; Gschwend JE; Retz M
Urologe A; 2012 Mar; 51(3):390-7. PubMed ID: 22331349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]